2024
Hospital COVID-19 Burden and Adverse Event Rates
Metersky M, Rodrick D, Ho S, Galusha D, Timashenka A, Grace E, Marshall D, Eckenrode S, Krumholz H. Hospital COVID-19 Burden and Adverse Event Rates. JAMA Network Open 2024, 7: e2442936. PMID: 39495512, PMCID: PMC11581512, DOI: 10.1001/jamanetworkopen.2024.42936.Peer-Reviewed Original ResearchConceptsCOVID-19 burdenHospital admissionPatient safetyRelative riskCohort studyStudy of hospital admissionsAcute care hospitalsRisk-adjustment variablesRisk-adjusted ratesMedicare hospital admissionsCOVID-19 pandemicStaffing shortagesHospital characteristicsMain OutcomesHospital resilienceSurge capacityMedicare patientsCare hospitalHighest burdenPrevent declinesPatient admissionsStudy sampleElixhauser comorbiditiesCOVID-19Low burden
2023
Prevalence of covid-19 and long covid in collegiate student athletes from spring 2020 to fall 2021: a retrospective survey
Massey D, Saydah S, Adamson B, Lincoln A, Aukerman D, Berke E, Sikka R, Krumholz H. Prevalence of covid-19 and long covid in collegiate student athletes from spring 2020 to fall 2021: a retrospective survey. BMC Infectious Diseases 2023, 23: 876. PMID: 38093182, PMCID: PMC10717379, DOI: 10.1186/s12879-023-08801-z.Peer-Reviewed Original ResearchConceptsLong COVIDCOVID-19SARS-CoV-2 infectionPost-acute sequelaeSymptomatic COVID-19SARS-CoV-2Student athletesPost-COVID conditionsMental health consequencesHealthy athletesCollegiate Student-AthletesHealthy peopleRetrospective surveyMore weeksHealth consequencesPrevalenceConclusionsThis studyConvenience sampleFall 2020College athletesFurther studiesAthletesCOVIDSpring 2020Relevant time periodDistinguishing features of long COVID identified through immune profiling
Klein J, Wood J, Jaycox J, Dhodapkar R, Lu P, Gehlhausen J, Tabachnikova A, Greene K, Tabacof L, Malik A, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott I, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng T, Xu L, Geraghty A, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick J, Kaminski N, Omer S, Krumholz H, Guan L, Dela Cruz C, van Dijk D, Ring A, Putrino D, Iwasaki A. Distinguishing features of long COVID identified through immune profiling. Nature 2023, 623: 139-148. PMID: 37748514, PMCID: PMC10620090, DOI: 10.1038/s41586-023-06651-y.Peer-Reviewed Original ResearchConceptsLong COVIDSARS-CoV-2Infection syndromeExaggerated humoral responseSoluble immune mediatorsEpstein-Barr virusPost-exertional malaiseCross-sectional studyHigher antibody responseImmune mediatorsImmune phenotypingImmune profilingHumoral responseAntibody responseLymphocyte populationsCOVID statusUnbiased machineCortisol levelsLC statusRelevant biomarkersViral pathogensSyndromeCOVIDFuture studiesBiological featuresShort- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study
Chemaitelly H, Faust J, Krumholz H, Ayoub H, Tang P, Coyle P, Yassine H, Al Thani A, Al-Khatib H, Hasan M, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal A, Latif A, Shaik R, Abdul-Rahim H, Nasrallah G, Al-Kuwari M, Butt A, Al-Romaihi H, Al-Thani M, Al-Khal A, Bertollini R, Abu-Raddad L. Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study. International Journal Of Infectious Diseases 2023, 136: 81-90. PMID: 37717648, DOI: 10.1016/j.ijid.2023.09.005.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioPrimary infection cohortCause mortalityCohort studyPrimary infectionMortality incidencePrimary SARS-CoV-2 infectionSARS-CoV-2-infected individualsCox proportional hazards regression modelSARS-CoV-2 infectionProportional hazards regression modelsRetrospective cohort studySevere COVID-19Cause mortality riskNational cohort studyCOVID-19 mortalityInfection cohortHazard ratioUnvaccinated personsVaccination statusVaccinated personsMortality riskVulnerable personsAccelerated onsetCohort
2022
Association of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being 3 Months After a Symptomatic Illness
Wisk L, Gottlieb M, Spatz E, Yu H, Wang R, Slovis B, Saydah S, Plumb I, O’Laughlin K, Montoy J, McDonald S, Lin Z, Lin J, Koo K, Idris A, Huebinger R, Hill M, Gentile N, Chang A, Anderson J, Hota B, Venkatesh A, Weinstein R, Elmore J, Nichol G, Santangelo M, Ulrich A, Li S, Kinsman J, Krumholz H, Dorney J, Stephens K, Black K, Morse D, Morse S, Fernandes A, Sharma A, Stober T, Geyer R, Lyon V, Adams K, Willis M, Ruiz L, Park J, Malone K, Shughart H, Schaeffer K, Shughart L, Arab A, Grau D, Patel A, Watts P, Kelly M, Hunt A, Hannikainen P, Chalfin M, Cheng D, Miao J, Shutty C, Chavez S, Kane A, Marella P, Gallegos G, Martin K, L'Hommedieu M, Chandler C, Diaz Roldan K, Villegas N, Moreno R, Eguchi M, Rodriguez R, Kemball R, Chan V, Chavez C, Wong A, Hall A, Briggs-Hagen M. Association of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being 3 Months After a Symptomatic Illness. JAMA Network Open 2022, 5: e2244486. PMID: 36454572, PMCID: PMC9716377, DOI: 10.1001/jamanetworkopen.2022.44486.Peer-Reviewed Original ResearchConceptsCOVID-19 positive groupCOVID-19-negative groupSARS-CoV-2 infectionCOVID-19 testCOVID-19 resultsSymptomatic illnessSymptomatic SARS-CoV-2 infectionNegative COVID-19 resultsSARS-CoV-2 statusSARS-CoV-2 test positivityPositive COVID-19 testSARS-CoV-2 testNegative COVID-19 testLongitudinal registry studyOutcomes Measurement Information SystemPatient-reported outcomesHealth care usePositive COVID-19 resultMultivariable regression analysisMeasurement Information SystemCOVID-19 testingNegative test resultsCohort studyRegistry studyPROMIS scoresUncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state
Faust JS, Renton B, Chen AJ, Du C, Liang C, Li SX, Lin Z, Krumholz HM. Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state. The Lancet Infectious Diseases 2022, 22: 1419-1420. PMID: 36007530, PMCID: PMC9395168, DOI: 10.1016/s1473-3099(22)00547-3.Peer-Reviewed Original ResearchExcess Mortality in Massachusetts During the Delta and Omicron Waves of COVID-19
Faust JS, Du C, Liang C, Mayes KD, Renton B, Panthagani K, Krumholz HM. Excess Mortality in Massachusetts During the Delta and Omicron Waves of COVID-19. JAMA 2022, 328: 74-76. PMID: 35594035, PMCID: PMC9257575, DOI: 10.1001/jama.2022.8045.Peer-Reviewed Original ResearchDurable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes
INVESTIGATORS I, Sadeghipour P, Talasaz A, Barco S, Bakhshandeh H, Rashidi F, Rafiee F, Rezaeifar P, Jamalkhani S, Matin S, Baghizadeh E, Tahamtan O, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M, Sezavar S, Payandemehr P, Dabbagh A, Moghadam K, Jimenez D, Monreal M, Maleki M, Siegerink B, Spatz E, Piazza G, Parikh S, Kirtane A, Van Tassell B, Lip G, Goldhaber S, Klok F, Krumholz H, Bikdeli B. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes. European Journal Of Internal Medicine 2022, 103: 76-83. PMID: 35879217, PMCID: PMC9212871, DOI: 10.1016/j.ejim.2022.06.014.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsCOVID-19Critical CareFemaleHospitalizationHumansMaleMiddle AgedSARS-CoV-2ConceptsStandard-dose prophylactic anticoagulationPatient Health Questionnaire-2Proportion of patientsProphylactic anticoagulationIntermediate doseFunctional limitationsDepressive symptomsFunctional outcomeCOVID-19Intensive care unit hospitalizationCritically Ill PatientsMultiple organ failureSevere functional limitationsFunctional Status ScaleCoronavirus disease 2019Open labelExercise limitationAirway diseaseICU patientsOrgan failureIntensive careStatus ScaleClinical trialsGrade 3AnticoagulationStudy protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection
O’Laughlin K, Thompson M, Hota B, Gottlieb M, Plumb ID, Chang AM, Wisk LE, Hall AJ, Wang RC, Spatz ES, Stephens KA, Huebinger RM, McDonald SA, Venkatesh A, Gentile N, Slovis BH, Hill M, Saydah S, Idris AH, Rodriguez R, Krumholz HM, Elmore JG, Weinstein RA, Nichol G, . Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. PLOS ONE 2022, 17: e0264260. PMID: 35239680, PMCID: PMC8893622, DOI: 10.1371/journal.pone.0264260.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionLong-term sequelaePatient-reported outcomesRelative riskAcute SARS-CoV-2 infectionSARS-CoV-2 negative participantsHealth system encountersPredictors of sequelaeHealth recordsInstitutional review board approvalLongitudinal studyDigital health recordsReview board approvalSARS-CoV-2Secure online platformClinical outcomesStudy protocolNegative participantsViral testsSimilar symptomatologyNew diagnosisBoard approvalSequelaeSelf-administered surveyInfectionChanges in Emergency Department Arrival Times for Acute Myocardial Infarction During the COVID-19 Pandemic Suggest Delays in Care Seeking
Janke AT, Gettel CJ, Haimovich A, Kocher KE, Krumholz HM, Venkatesh AK. Changes in Emergency Department Arrival Times for Acute Myocardial Infarction During the COVID-19 Pandemic Suggest Delays in Care Seeking. Circulation Cardiovascular Quality And Outcomes 2022, 15: e008402. PMID: 35105172, PMCID: PMC8833230, DOI: 10.1161/circoutcomes.121.008402.Peer-Reviewed Original ResearchPhysical Activity Among Patients With Intracardiac Remote Monitoring Devices Before, During, and After COVID-19–Related Restrictions
Lu Y, Jones PW, Murugiah K, Caraballo C, Massey DS, Mahajan S, Ahmed R, Bader EM, Krumholz HM. Physical Activity Among Patients With Intracardiac Remote Monitoring Devices Before, During, and After COVID-19–Related Restrictions. Journal Of The American College Of Cardiology 2022, 79: 309-310. PMID: 35057917, PMCID: PMC8763290, DOI: 10.1016/j.jacc.2021.11.010.Peer-Reviewed Original Research
2021
Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes
Khera R, Liu Y, de Lemos JA, Das SR, Pandey A, Omar W, Kumbhani DJ, Girotra S, Yeh RW, Rutan C, Walchok J, Lin Z, Bradley SM, Velazquez EJ, Churchwell KB, Nallamothu BK, Krumholz HM, Curtis JP. Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes. The American Journal Of Medicine 2021, 134: 1380-1388.e3. PMID: 34343515, PMCID: PMC8325555, DOI: 10.1016/j.amjmed.2021.06.034.Peer-Reviewed Original ResearchConceptsCOVID-19 hospitalizationHospitalization volumeAmerican Heart Association COVID-19 Cardiovascular Disease RegistryCase volumeUS hospitalsCoronavirus disease 2019 (COVID-19) hospitalizationIntensive care unit therapyHospital case fatality ratePoor COVID-19 outcomesCardiovascular Disease RegistryHospital case volumeCase fatality rateCOVID-19 outcomesHospital bed capacityLowest quartilePatient outcomesHospital careHigher oddsTriage strategiesFuture health challengesDisease RegistryMedical treatmentEarly identificationHospitalSignificant associationEngagement With COVID-19 Public Health Measures in the United States: A Cross-sectional Social Media Analysis from June to November 2020
Massey D, Huang C, Lu Y, Cohen A, Oren Y, Moed T, Matzner P, Mahajan S, Caraballo C, Kumar N, Xue Y, Ding Q, Dreyer R, Roy B, Krumholz H. Engagement With COVID-19 Public Health Measures in the United States: A Cross-sectional Social Media Analysis from June to November 2020. Journal Of Medical Internet Research 2021, 23: e26655. PMID: 34086593, PMCID: PMC8218897, DOI: 10.2196/26655.Peer-Reviewed Original ResearchIntermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial
Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, Baghizadeh E, Matin S, Jamalkhani S, Tahamtan O, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Khalili H, Yadollahzadeh M, Riahi T, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abri H, Tabrizi S, Mousavian SM, Shahmirzaei S, Amin A, Mohebbi B, Parhizgar SE, Aliannejad R, Eslami V, Kashefizadeh A, Dobesh PP, Kakavand H, Hosseini SH, Shafaghi S, Ghazi SF, Najafi A, Jimenez D, Gupta A, Madhavan MV, Sethi SS, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane AJ, Van Tassell BW, Stone GW, Lip GYH, Krumholz H, Goldhaber SZ, Sadeghipour P. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis And Haemostasis 2021, 122: 131-141. PMID: 33865239, DOI: 10.1055/a-1485-2372.Peer-Reviewed Original ResearchConceptsStandard-dose prophylactic anticoagulationExtracorporeal membrane oxygenationProphylactic anticoagulationIntermediate doseEfficacy outcomesArterial thrombosisCOVID-19Hospital discharge statusMain safety outcomeProphylactic antithrombotic therapyComposite of deathCritically Ill PatientsPrimary efficacy outcomeStandard-dose groupIntermediate-dose groupIntensive care unitCoronavirus disease 2019Cause deathMajor bleedingModified intentionOpen labelAntithrombotic therapyExtrapulmonary manifestationsHospital dischargeThrombotic complicationsLeveraging Remote Physiologic Monitoring in the COVID-19 Pandemic to Improve Care After Cardiovascular Hospitalizations
Dey P, Jarrin R, Mori M, Geirsson A, Krumholz HM. Leveraging Remote Physiologic Monitoring in the COVID-19 Pandemic to Improve Care After Cardiovascular Hospitalizations. Circulation Cardiovascular Quality And Outcomes 2021, 14: e007618-e007618. PMID: 33820445, PMCID: PMC8059759, DOI: 10.1161/circoutcomes.120.007618.Peer-Reviewed Original ResearchAssociation between antecedent statin use and decreased mortality in hospitalized patients with COVID-19
Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA, Redfors B, Eckhardt C, Bikdeli B, Platt J, Nalbandian A, Elias P, Cummings MJ, Nouri SN, Lawlor M, Ranard LS, Li J, Boyle C, Givens R, Brodie D, Krumholz HM, Stone GW, Sethi SS, Burkhoff D, Uriel N, Schwartz A, Leon MB, Kirtane AJ, Wan EY, Parikh SA. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nature Communications 2021, 12: 1325. PMID: 33637713, PMCID: PMC7910606, DOI: 10.1038/s41467-021-21553-1.Peer-Reviewed Original ResearchConceptsAcute respiratory distress syndromeStatin usePrimary endpointCOVID-19Multivariable logistic regression modelStudy periodLower inpatient mortalityPropensity-matched cohortRespiratory distress syndromeCoronavirus disease 2019Electronic medical recordsLogistic regression modelsPropensity-score matchingHospital mortalityHyperinflammatory stateOutpatient medicationsClinical characteristicsInpatient mortalityStatin usersThrombotic complicationsDistress syndromeHospitalized patientsMyocardial injuryMedical recordsRetrospective analysisSARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut
Mahajan S, Caraballo C, Li SX, Dong Y, Chen L, Huston SK, Srinivasan R, Redlich CA, Ko AI, Faust JS, Forman HP, Krumholz HM. SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut. The American Journal Of Medicine 2021, 134: 812-816.e2. PMID: 33617808, PMCID: PMC7895685, DOI: 10.1016/j.amjmed.2021.01.020.Peer-Reviewed Original ResearchConceptsInfection hospitalization rateInfection fatality rateHospitalization ratesFatality rateSeroprevalence estimatesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2 antibodiesConnecticut Hospital AssociationNon-Hispanic black peopleProportion of deathsCoronavirus disease 2019Total infected individualsTotal hospitalizationsAdverse outcomesNon-congregate settingsHigh burdenDisease 2019Prevalence studyMost subgroupsInfected individualsHospitalizationOlder peopleHospital AssociationConnecticut DepartmentDeath
2020
SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity
Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, Caraballo C, Kalinich CC, Ott IM, Fauver JR, Kudo E, Lu P, Venkataraman A, Tokuyama M, Moore AJ, Muenker MC, Casanovas-Massana A, Fournier J, Bermejo S, Campbell M, Datta R, Nelson A, Team Y, Anastasio K, Askenase M, Batsu M, Bickerton S, Brower K, Bucklin M, Cahill S, Cao Y, Courchaine E, DeIuliis G, Earnest R, Geng B, Goldman-Israelow B, Handoko R, Khoury-Hanold W, Kim D, Knaggs L, Kuang M, Lapidus S, Lim J, Linehan M, Lu-Culligan A, Martin A, Matos I, McDonald D, Minasyan M, Nakahata M, Naushad N, Nouws J, Obaid A, Odio C, Oh J, Omer S, Park A, Park H, Peng X, Petrone M, Prophet S, Rice T, Rose K, Sewanan L, Sharma L, Shaw A, Shepard D, Smolgovsky M, Sonnert N, Strong Y, Todeasa C, Valdez J, Velazquez S, Vijayakumar P, White E, Yang Y, Dela Cruz C, Ko A, Iwasaki A, Krumholz H, Matheus J, Hui P, Liu C, Farhadian S, Sikka R, Wyllie A, Grubaugh N. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. Med 2020, 2: 263-280.e6. PMID: 33521748, PMCID: PMC7836249, DOI: 10.1016/j.medj.2020.12.010.Peer-Reviewed Original ResearchConceptsEmergency use authorizationSARS-CoV-2 testingSARS-CoV-2 screeningSARS-CoV-2 testing capacitySupply chain shortagesHospital cohortNasopharyngeal swabsHealthy individualsDrug AdministrationHigh positive agreementQRT-PCR assaysDiagnostic testsU.S. FoodSafe reopeningTesting capacityGlobal healthPositive agreementFast GrantLower ratesSalivaNucleic acid extractionSwabsValid alternativeAssay costsCollection tubesSeroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study
Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, Massey DS, Dugan A, Witters D, Marlar J, Li SX, Lin Z, Hodge D, Chattopadhyay M, Adams MD, Lee C, Rao LV, Stewart C, Kuppusamy K, Ko AI, Krumholz HM. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. The American Journal Of Medicine 2020, 134: 526-534.e11. PMID: 33130124, PMCID: PMC7598362, DOI: 10.1016/j.amjmed.2020.09.024.Peer-Reviewed Original ResearchConceptsSARS-CoV-2-specific IgG antibodiesWeighted seroprevalenceIgG antibodiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2-specific antibodiesConnecticut residentsSelf-reported adherenceImmunoglobulin G antibodiesSARS-CoV-2Symptomatic illnessSerology testingSeroprevalence studyG antibodiesPrevalence studyGeneral populationPercentage of peopleSeroprevalenceLack antibodiesMajority of respondentsAntibodiesHispanic subpopulationsConvenience sampleHispanic populationCOVID-19Risk mitigation behaviorsCharacteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov
Pundi K, Perino AC, Harrington RA, Krumholz HM, Turakhia MP. Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov. JAMA Internal Medicine 2020, 180: 1398-1400. PMID: 32730617, PMCID: PMC7385669, DOI: 10.1001/jamainternmed.2020.2904.Peer-Reviewed Original Research